Literature DB >> 2810475

In vitro activity of five tetracyclines and some other antimicrobial agents against four porcine respiratory tract pathogens.

A Pijpers1, B Van Klingeren, E J Schoevers, J H Verheijden, A S Van Miert.   

Abstract

The minimal inhibitory concentrations (MIC) of five tetracyclines and ten other antimicrobial agents were determined for four porcine bacterial respiratory tract pathogens by the agar dilution method. For the following oxytetracycline-susceptible strains, the MIC50 ranges of the tetracyclines were: P. multocida (n = 17) 0.25-0.5 micrograms/ml; B. bronchiseptica (n = 20) 0.25-1.0 micrograms/ml; H. pleuropneumoniae (n = 20) 0.25-0.5 micrograms/ml; S. suis Type 2 (n = 20) 0.06-0.25 micrograms/ml. For 19 oxytetracycline-resistant P. multocida strains the MIC50 of the tetracyclines varied from 64 micrograms/ml for oxytetracycline to 0.5 micrograms/ml for minocycline. Strikingly, minocycline showed no cross-resistance with oxytetracycline, tetracycline, chlortetracycline and doxycycline in P. multocida and in H. pleuropneumoniae. Moreover, in susceptible strains minocycline showed the highest in vitro activity followed by doxycycline. Low MIC50 values were observed for chloramphenicol, ampicillin, flumequine, ofloxacin and ciprofloxacin against P. multocida and H. pleuropneumoniae. B. bronchiseptica was moderately susceptible or resistant to these compounds. As expected tiamulin, lincomycin, tylosin and spiramycin were not active against H. pleuropneumoniae. Except for flumequine, the MIC50 values of nine antimicrobial agents were low for S. suis Type 2. Six strains of this species showed resistance to the macrolides and lincomycin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2810475     DOI: 10.1111/j.1365-2885.1989.tb00670.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  9 in total

1.  Antimicrobial susceptibility of Bordetella bronchiseptica isolates from porcine respiratory tract infections.

Authors:  Kristina Kadlec; Corinna Kehrenberg; Jürgen Wallmann; Stefan Schwarz
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  Flumequine in the goat: pharmacokinetics after intravenous and intramuscular administration.

Authors:  R Villa; P Cagnardi; O Sonzogni; S Carli
Journal:  Vet Res Commun       Date:  2005-11       Impact factor: 2.459

3.  Pharmacokinetics of amoxicillin trihydrate in Desert sheep and Nubian goats.

Authors:  H A Elsheikh; A A Taha; A E Khalafalla; I A Osman; I A Wasfi
Journal:  Vet Res Commun       Date:  1999-12       Impact factor: 2.459

4.  Comparative in vitro activity of 16 antimicrobial agents against Actinobacillus pleuropneumoniae.

Authors:  H Yoshimura; M Takagi; M Ishimura; Y S Endoh
Journal:  Vet Res Commun       Date:  2002-01       Impact factor: 2.459

5.  Aspects of the pharmacokinetics of doxycycline given to healthy and pneumonic East African dwarf goats by intramuscular injection.

Authors:  I M Ole-Mapenay; E S Mitema; T E Maitho
Journal:  Vet Res Commun       Date:  1997-08       Impact factor: 2.459

Review 6.  Human infections associated with Bordetella bronchiseptica.

Authors:  B F Woolfrey; J A Moody
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

7.  Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates.

Authors:  Ehab A Abu-Basha; Nasir M Idkaidek; Tareq M Hantash
Journal:  J Vet Sci       Date:  2006-12       Impact factor: 1.672

8.  Antimicrobial Susceptibility of Bordetella bronchiseptica Isolates from Swine and Companion Animals and Detection of Resistance Genes.

Authors:  Sandra Prüller; Ulrike Rensch; Diana Meemken; Heike Kaspar; Peter A Kopp; Günter Klein; Corinna Kehrenberg
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

9.  Doxycycline pharmacokinetics in geese.

Authors:  Irene Sartini; Beata Łebkowska-Wieruszewska; Andrzej Lisowski; Amnart Poapolathep; Andrejs Sitovs; Mario Giorgi
Journal:  J Vet Pharmacol Ther       Date:  2021-07-27       Impact factor: 1.567

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.